newsfilter
← Latest News
Business Wire·

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

- Company Now Exclusively Focused on Development and Commercialization of Abecma - 2seventy bio, Inc. (NASDAQ:TSVT), announced today the completion of the asset purchase agreement ("APA") by Regeneron Pharmaceuticals,